In glioblastoma, the aberrant behavior of cancer stem cells contributes significantly to tumor initiation, resistance to therapies, and recurrence after treatment. These stem cells possess the unique ability to self-renew and differentiate into various types of brain tumors. Understanding the molecular pathways that regulate their properties is critical for developing effective treatment strategies. The researchers focused their investigation on the NSUN7 enzyme and its association with the modification of circular RNA molecules, particularly circNTRK2.

Circular RNAs have emerged as a new class of regulatory molecules in various biological processes. Unlike linear RNAs, these molecules form a covalently closed continuous loop, which allows them to exhibit distinct properties, such as greater stability and unique interaction capabilities with proteins and other RNAs. The researchers hypothesized that circNTRK2 might be involved in temozolomide resistance, a common treatment for glioblastoma. The NSUN7 enzyme plays a pivotal role in the N^5-methylcytosine (m^5C) modification of RNA, which is known to influence RNA stability and function.

In examining the activities of NSUN7, the research team conducted a series of experiments that demonstrated the correlation between NSUN7 expression levels and the stemness properties of glioblastoma cells. Their findings revealed that enhanced NSUN7 activity led to increased m^5C modification of circNTRK2, which in turn activated the STK31 protein. STK31 is crucial for maintaining the stem-like characteristics of glioblastoma cells, suggesting that the m^5C modification serves as a regulatory switch in this context.

One of the most compelling aspects of this research was the demonstration of the functional implications of NSUN7-induced m^5C modification. The authors conducted in vitro assays that showcased how the introduction of a specific inhibitor targeting the NSUN7 enzyme diminished the stemness features of glioblastoma cells. This was accompanied by reduced cell proliferation, increased apoptosis, and diminished abilities to form spheres, a hallmark of stem cell behavior in vitro.

Furthermore, the in vivo component of the study involved the use of xenograft models to evaluate how NSUN7 modulation influences tumor growth and progression in a living organism. The results were striking: tumors derived from cells with inhibited NSUN7 showed significantly reduced growth rates and alterations in their histological characteristics. These findings not only corroborate the role of the NSUN7-circNTRK2-STK31 pathway but also underline its potential as a therapeutic target.

Given the challenges posed by glioblastoma, particularly its notorious resistance to conventional therapies, this research paves the way for novel treatment approaches. By targeting the m^5C modification pathway intertwined within the glioblastoma stem cell compartment, it may be possible to develop strategies that can sensitize tumors to existing treatments while simultaneously depleting their stem-like populations.

Moreover, the implications of this research extend beyond glioblastoma. The N^5-methylcytosine modification is increasingly recognized as a crucial post-transcriptional modification that could influence various other malignancies and cellular contexts. Thus, further exploration into the dynamics of RNA modifications holds promise for broadening our understanding of cancer biology and therapeutic intervention.

While the research makes significant inroads, there are various avenues for future inquiry. The interplay between different RNA modifications, such as m^5C and N6-methyladenosine, is not well understood and could hold keys to unraveling further complexities of RNA regulation in cancer. Additionally, the exploration of the broader RNA landscape in glioblastoma could reveal more targets for intervention and deeper insights into the behaviors of cancer stem cells.

Furthermore, the precise molecular mechanisms through which NSUN7-modified circNTRK2 influences STK31 activity warrant deeper exploration. Understanding the interactions at the molecular level could pave the way toward developing small molecules or biologics that could specifically target these pathways in glioblastoma.

The community eagerly anticipates follow-up studies as they could enrich the conversation surrounding RNA modifications in cancer research. As our understanding of non-coding RNAs and their modifications deepens, the potential for RNA-based therapeutics could become a tangible reality.

In conclusion, the research conducted by Zhao et al. shines a beacon of hope in the fight against glioblastoma, emphasizing the role of RNA modifications in cancer biology. This study not only elucidates a novel regulatory mechanism governing glioblastoma stemness but also opens new doors for potential therapeutic strategies targeting resistant populations in this devastating disease.

Subject of Research: NSUN7-mediated RNA modifications and their impact on glioblastoma stemness.

Article Title: NSUN7-mediated m⁵C modification of circNTRK2 regulates stemness properties of glioblastoma cells by activating STK31.

Article References:

Zhao, Y., Zhang, M., Ma, J. et al. NSUN7-mediated m⁵C modification of circNTRK2 regulates stemness properties of glioblastoma cells by activating STK31. J Transl Med (2025). https://doi.org/10.1186/s12967-025-07484-1

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07484-1

Keywords: glioblastoma, cancer stem cells, RNA modification, NSUN7, circNTRK2, STK31, N^5-methylcytosine.

DNA helicases are vital enzymes responsible for unwinding DNA strands, a necessary process during replication, repair, and recombination. Within human cells, the RecQ family of helicases plays a pivotal role in maintaining genome stability, a factor critical in preventing cancer development. Among these, RECQL4 and BLM stand out due to their involvement in DNA replication stress responses and DNA damage repair pathways. Prior studies have established the overexpression of these helicases in glioblastoma, yet the differential contributions of RECQL4 and BLM to chemotherapy resistance had remained unclear until now.

Glioblastoma’s notorious resistance to conventional therapies such as temozolomide (TMZ), a standard alkylating agent, and newer treatments involving PARP inhibitors like olaparib (OLA), poses significant treatment challenges. Previous research showed that BLM depletion in glioma cells results in senescence-associated or polyploid phenotypic shifts when exposed to TMZ and OLA. However, the specific effects of RECQL4 depletion under similar conditions were largely uncharted territory, prompting the authors to explore how RECQL4 influences glioma cellular responses to chemotherapeutics.

To investigate this, the researchers engineered glioma cell lines with knocked-out RECQL4 (RQ4 KO) and compared them to those lacking BLM expression (BLM KO). Using LN18 and LN229 glioma cells, comprehensive analyses were conducted focusing on cell viability, apoptosis induction, senescence markers, polyploidization, and changes in cell cycle dynamics. High-throughput transcriptomic profiling was also performed to elucidate the global gene expression alterations resulting from depletion of either helicase.

Interestingly, unlike BLM deletion, which led to distinct phenotypic outcomes, RECQL4 depletion elicited profound changes in the transcriptome that were largely unique and non-overlapping with those observed in BLM-deficient cells. This divergence even influenced how these cells responded to chemotherapeutic agents. While both RQ4 KO and BLM KO cells demonstrated only modest effects on baseline proliferation and viability, RECQL4-deficient glioma cells showed heightened sensitivity to combined TMZ and OLA treatment, exhibiting marked decreases in survival coupled with elevated apoptotic activity.

Contrary to BLM-depleted cells, which underwent senescence or polyploidy upon drug exposure, the RECQL4 knockout cells resisted such phenotypic shifts. Instead, these cells experienced cell cycle arrest without entering senescence or exhibiting polyploid nuclei, highlighting a mechanistic dichotomy in how these helicases modulate cell fate under chemotherapy-induced stress. This distinction may inform more precise strategies to exploit helicase function for therapeutic gain.

Another unexpected finding was the relative resistance of both RQ4 KO and BLM KO cells to WP744, a novel doxorubicin derivative with potent anti-tumor activity. This resistance contrasted with the wild-type LN229 glioma cells’ sensitivity and suggests that RECQL4 and BLM may also influence responses to certain anthracycline-based agents, adding a layer of complexity to treatment design and drug development.

The implications of these findings are profound. They underscore the non-redundant roles of RECQL4 and BLM helicases in managing DNA repair and cell cycle progression upon chemotherapy, thereby shaping therapeutic outcomes in glioblastoma. Targeting RECQL4, in particular, emerges as a compelling option to augment the efficacy of existing chemotherapeutic regimens, potentially overcoming resistance mechanisms that have stymied progress in treating this fatal cancer.

This study also opens the door for future exploration into the molecular pathways downstream of RECQL4 and BLM activity. Understanding how these helicases interact with other DNA repair proteins, signaling cascades, and cellular checkpoints could reveal novel targets and biomarkers predictive of treatment response. Moreover, discerning their roles across different glioma subtypes and patient-derived models will be crucial for translating these insights into clinical practice.

RECQL4’s unique transcriptomic footprint observed here may reveal vulnerabilities in glioma cells that can be exploited therapeutically. For example, drugs that mimic RECQL4 depletion or inhibit its helicase activity might synergize with TMZ and PARP inhibitors, enhancing tumor cell kill while sparing normal tissues. However, given the ubiquitous necessity of RecQ helicases for genome integrity in normal cells, therapeutic approaches must be carefully tailored to minimize collateral damage.

Overall, this study exemplifies the growing recognition that effectively tackling glioblastoma requires detailed knowledge of the molecular underpinnings of chemoresistance. By disentangling the distinct molecular roles of helicases like RECQL4 and BLM, researchers pave the way for innovative strategies that could finally improve outcomes for patients suffering from this devastating disease.

The challenge remains formidable, yet the new data presented by Wojnicki and colleagues provide hope and direction. As research continues to uncover the intricate dance between tumor genetics and treatment response, personalized therapeutic regimens leveraging helicase targeting may become an integral part of glioblastoma management in the near future.

In conclusion, the complex interplay between RECQL4 and BLM helicases represents a frontier in cancer biology that bridges DNA repair dynamics with chemotherapeutic efficacy. This latest work urges oncologists and molecular biologists alike to consider these enzymes as both biomarkers and therapeutic targets in the ongoing quest to outmaneuver glioblastoma.

Subject of Research:
The study focuses on the differential and shared functions of RECQL4 and BLM helicases in DNA damage response pathways, particularly in how their depletion affects glioma cell survival, apoptosis, senescence, and drug resistance following chemotherapy exposure.

Article Title:
Shared and non-overlapping functions of RECQL4 and BLM helicases in chemotherapeutics-induced glioma cell responses

Article References:
Wojnicki, K., Wojtas, B., Ciechomska, I.A. et al. Shared and non-overlapping functions of RECQL4 and BLM helicases in chemotherapeutics-induced glioma cell responses. BMC Cancer 25, 1434 (2025). https://doi.org/10.1186/s12885-025-14932-0

Image Credits: Scienmag.com

DOI:
https://doi.org/10.1186/s12885-025-14932-0